donepezil has been researched along with decamethonium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrisano, V; Bartolini, M; Bidon-Chanal, A; de Austria, C; del Monte-Millán, M; Dorronsoro, I; García-Palomero, E; Luque, FJ; Martínez, A; Medina, M; Muñoz-Ruiz, P; Orozco, M; Rubio, L; Usán, P; Valenzuela, R | 1 |
| Aluisio, L; Apodaca, R; Barbier, AJ; Bembenek, SD; Carruthers, NI; Dvorak, L; Keith, JM; Letavic, MA; Lovenberg, TW; Miller, KL | 1 |
2 other study(ies) available for donepezil and decamethonium
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cell Line, Tumor; Cholinesterase Inhibitors; Dimerization; Drug Design; Erythrocytes; Fluorometry; Humans; Models, Molecular; Nootropic Agents; Protein Binding; Structure-Activity Relationship; Tacrine | 2005 |
Lead identification of acetylcholinesterase inhibitors-histamine H3 receptor antagonists from molecular modeling.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Histamine H3 Antagonists; Humans; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |